5 Key Takeaways | Best Practices in Patent Drafting: Addressing 112 and Enablement after Amgen
On July 16 2025, the Court of Appeal dismissed AstraZeneca’s appeal and upheld the first instance decision, finding that AstraZeneca’s compound patent for dapagliflozin, an SGLT2 inhibitor used to treat diabetes, was invalid...more